Ela DELİKGÖZ SOYKUT, Yasemin KEMAL, Eylem ODABAŞI, Nilgün ŞAHİN, Betül KESKİNKILIÇ YAĞIZ, İrem Melike YAZICIOĞLU, Süheyla AYTAÇ ARSLAN, Yıldız GÜNEY

Pre-Treatment and Post-Treatment Neutrophil-to- Lymphocyte Ratio Predict Pathological Tumor Response and Survival in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

OBJECTIVE The aim of this study is to investigate the relationship between baseline and post-treatment neutrophil- to-lymphocyte ratio (NLR) levels and response to neoadjuvant chemoradiotherapy (CRT) in terms of good pathological response and survival. METHODS Fifty-six patients who underwent neoadjuvant CRT and curative surgery for locally advanced rectal cancer (LARC) were analyzed retrospectively. Pre-CRT and post-CRT hematologic parameters were recorded. The link between NLR and clinical outcomes was explored. RESULTS The receiver operating characteristic analysis revealed appropriate cut-off values of 2.87 for pre-CRT NLR associated with good pathological response and 8.68 for post-CRT NLR predicting survival. The low pre-CRT NLR group had better outcomes in terms of good pathological response compared to the high pre-CRT NLR group (OR 4.15, 95% CI 1.23-13.76, p=0.021). However, the analysis failed to show the correlation between NLR and pCR (OR 2.74, 95% CI 0.37-20.15, p=0.320). Patients with elevated post-CRT NLR had significantly worse 5-year overall survival (OS), disease-free survival (DFS) and local regional recurrence-free survival (LRRFS) rates compared to low post-CRT NLR in multivariate analysis (46.6% vs. 74.4%, p=0.020; 35.3% vs. 71.9%, p=0.018; 40.8% vs. 78.1%, p=0.006). CONCLUSION High pre-CRT NLR might be used as a poor pathological tumor response predictor in LARC patients treated with neoadjuvant CRT. In addition, low post-CRT NLR is associated with favorable OS, DFS, and LRRFS. Therefore, easily accessible and cost-effective NLR can be considered as a potential predic- tive marker to identify patients and establish personalized treatment strategies.

PDF

___

1. Sauer R, Becker H, Hohenberger W, Rödel C, Wit- tekind C, Fietkau R, et al. German Rectal Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351(17):1731−40.
2. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual pa- tient data. Lancet Oncol 2010;11(9):835–44.
3. Grivennikov SI, Greten FR, Karin M. Immunity, in- flammation, and cancer. Cell 2010;140(6):883–99.
4. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neu- trophil-to-lymphocyte ratio in solid tumors: a sys- tematic review and meta-analysis. J Natl Cancer Inst 2014;106(6):dju124.
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflamma- tion based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88(1):218–30.
6. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response follow- ing long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47(2):141–6.
7. Hung HY, Chen JS, Yeh CY, Changchien CR, Tang R, Hsieh PS, et al. Effect of preoperative neutrophil- lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 2011;26(8):1059– 65.
8. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109(2):401–7.
9. Dong YW, Shi YQ, He LW, Su PZ. Prognostic signifi- cance of neutrophil-to-lymphocyte ratio in rectal can- cer: a meta-analysis. Onco Targets Ther 2016;9:3127–34.
10. Dudani S, Marginean H, Tang PA, Monzon JG, Rais- souni S, Asmis TR, et al. Neutrophil-to-lymphocyte and platelet-tolymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradia- tion. BMC Cancer 2019;19:664.
11. Carruthers R, Tho LM, Brown J, Kakumanu S, McCart- ney E, McDonald AC. Systemic inflammatory re- sponse is a predictor of outcome in patients undergo- ing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis 2012;14(10):e701–7.
12. Nagasaki T, Akiyoshi T, Fujimoto Y, Konishi T, Na- gayama S, Fukunaga Y, et al. Prognostic ımpact of neu- trophil-to-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemora- diotherapy. Dig Surg 2015;32(6):496–503.
13. Krauthamer M, Rouvinov K, Ariad S, Man S, Walfish S, Pinsk I, et al. A study of inflammation-based predic- tors of tumor response to neoadjuvant chemoradio- therapy for locally advanced rectal cancer. Oncology 2013;85(1):27–32.
14. Kim TG, Park W, Kim H, Choi DH, Park HC, Kim SH, et al. Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. Tumori 2019;105(5):434–40.
15. Shen J, Zhu Y, Wu W, Zhang L, Ju H, Fan Y, et al. Prog- nostic role of neutrophil-to-lymphocyte ratio in lo- cally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit 2017;23:315–24.
16. Kim IY, You SH, Kim YW. Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg 2014;14:94.
17. Lee IH, Hwang S, Lee SJ, Kang BW, Baek D, Kim HJ, et al. Systemic ınflammatory response after preoper- ative chemoradiotherapy can affect oncologic out- comes in locally advanced rectal cancer. Anticancer Res 2017;37(3):1459–65.
18. Rödel C, Graeven U, Fietkau R, Hoenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to flu- orouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16(8):979–89.
19. Theodoropoulos G, Wise WE, Padmanabhan A, Kerner BA, Taylor CW, Aguilar PS, et al. T-level down- staging and complete pathologic response after pre- operative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease- free survival. Dis Colon Rectum 2002;45(7):895–903.
20. van der Valk MJM, Hilling DE, Bastiaannet E, Kra- nenbarg EMK, Beets GL, Figueiredo NL, et al. Long term outcomes of clinical complete responders af- ter neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): An international multicentre registry study. Lancet 2018;391(10139):2537–45.
21. Andras D, Crisan D, Craciun R, Nemes A, Caziuc A, Drasovean R, et al. Neutrophil-to-lymphocyte ratio: a hidden gem in predicting neoadjuvant treatment response in locally advanced rectal cancer? J BUON 2020;25(3):1436–42